NO20075834L - Doseringsformer for risendronat - Google Patents
Doseringsformer for risendronatInfo
- Publication number
- NO20075834L NO20075834L NO20075834A NO20075834A NO20075834L NO 20075834 L NO20075834 L NO 20075834L NO 20075834 A NO20075834 A NO 20075834A NO 20075834 A NO20075834 A NO 20075834A NO 20075834 L NO20075834 L NO 20075834L
- Authority
- NO
- Norway
- Prior art keywords
- risedronate
- bisphosphonate
- chelator
- food
- small intestine
- Prior art date
Links
- 240000007594 Oryza sativa Species 0.000 title 1
- 235000007164 Oryza sativa Nutrition 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 235000009566 rice Nutrition 0.000 title 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 abstract 5
- 229940089617 risedronate Drugs 0.000 abstract 5
- 229940122361 Bisphosphonate Drugs 0.000 abstract 4
- 150000004663 bisphosphonates Chemical class 0.000 abstract 4
- 239000002738 chelating agent Substances 0.000 abstract 3
- 210000000813 small intestine Anatomy 0.000 abstract 3
- 239000006186 oral dosage form Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Abstract
Orale doseringsformer av et risedronat omfattende en sikker og effektiv mengde av en farmasøytisk sammensetning omfattende risedronat, en chelatdanner og innretninger for å utføre forsinket frigiving av risedronatet og chelatdanneren i tynntarmen, tilveiebringe umiddelbar frigiving av den farmasøytiske sammensetningen til tynntarmen i pattedyrindividet og farmasøytisk effektiv absorpsjon av bisfosfonatet med eller uten mat eller drikke. Foreliggende oppfinnelse letter vesentlig samvirket mellom risedronat og mat eller drikke, hvilket samvirke resulterer i at bisfosfonatet aktiv ingrediens ikke er tilgjengelig for absorpsjon. Den resulterende orale doseringsformen kan således tas med eller uten mat. Videre effektuerer foreliggende oppfinnelse avlevering av risedronat og chelatdanneren til tynntarmen, noe som vesentlig letter den øvre GI-irritasjonen forbundet med bisfosfonatterapier. Disse fordelene forenkler tidligere komplekse behandlingsregimer og kan føre til økt pasienttilfredshet med bisfosfonatterapier. ?? ?? ?? ??
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/106,816 US7645459B2 (en) | 2004-05-24 | 2005-04-15 | Dosage forms of bisphosphonates |
PCT/US2005/042887 WO2006112889A1 (en) | 2005-04-15 | 2005-11-23 | Dosage forms of risedronate |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20075834L true NO20075834L (no) | 2007-11-14 |
Family
ID=36190430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20075834A NO20075834L (no) | 2005-04-15 | 2007-11-14 | Doseringsformer for risendronat |
Country Status (16)
Country | Link |
---|---|
US (4) | US7645459B2 (no) |
EP (1) | EP1868584A1 (no) |
JP (1) | JP4788765B2 (no) |
KR (2) | KR101070205B1 (no) |
CN (2) | CN104027323A (no) |
AU (1) | AU2005330654B2 (no) |
BR (1) | BRPI0520082A2 (no) |
CA (2) | CA2602188C (no) |
IL (2) | IL186339A0 (no) |
IN (1) | IN2012DN00827A (no) |
MA (1) | MA29681B1 (no) |
MX (1) | MX2007012821A (no) |
NO (1) | NO20075834L (no) |
RU (1) | RU2381791C2 (no) |
SM (1) | SMAP200700047A (no) |
WO (1) | WO2006112889A1 (no) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7563460B2 (en) * | 2004-02-26 | 2009-07-21 | Med Five, Inc. | Enteric coated oral pharmaceutical to erode kidney stones |
US7645460B2 (en) * | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
US20080287400A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US20080286359A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
US20060134190A1 (en) * | 2004-12-16 | 2006-06-22 | Banner Pharmacaps Inc. | Formulations of bisphosphonate drugs with improved bioavailability |
EP1865928A1 (en) * | 2005-03-17 | 2007-12-19 | Elan Pharma International Limited | Nanoparticulate biphosphonate compositions |
US7473684B2 (en) * | 2005-09-16 | 2009-01-06 | Selamine Limited | Bisphosphonate formulation |
GB2430156A (en) * | 2005-09-16 | 2007-03-21 | Selamine Ltd | Bisphosphonate formulation |
US7201929B1 (en) * | 2005-12-30 | 2007-04-10 | Alan James Group, Llc. | Aspirin formulation for cardiovascular health |
US7202229B1 (en) * | 2005-12-30 | 2007-04-10 | Alan James Group, Llc. | Aspirin formulation for cardiovascular health |
GB0616794D0 (en) * | 2006-08-24 | 2006-10-04 | Arrow Int Ltd | Solid dosage form |
GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
AU2014201170B2 (en) * | 2006-12-20 | 2015-09-24 | Mylan Pharmaceuticals Ulc | Pharmaceutical composition comprising a hot-melt granulated lubricant |
WO2008074145A1 (en) * | 2006-12-20 | 2008-06-26 | Genpharm Ulc | Pharmaceutical composition comprising a hot-melt granulated lubricant |
WO2008153725A2 (en) | 2007-05-25 | 2008-12-18 | North Carolina State University | Viral nanoparticle cell-targeted delivery platform |
US8345282B2 (en) * | 2007-08-03 | 2013-01-01 | Kyocera Document Solutions Inc. | Image forming system and image forming apparatus |
WO2009018834A1 (en) * | 2007-08-06 | 2009-02-12 | Pharmathen S.A. | Pharmaceutical composition containing bisphosphonate and method for the preparation thereof |
EP2255199A1 (en) * | 2008-02-19 | 2010-12-01 | Jovesis Inc. | Microparticle compositions to modify cancer promoting cells |
JP2011529902A (ja) * | 2008-07-31 | 2011-12-15 | 味の素株式会社 | リセドロネートまたはその塩の低投与量形態 |
SG171362A1 (en) * | 2008-11-20 | 2011-07-28 | Avantor Performance Mat Inc | Directly compressible high functionality granular dibasic calcium phosphate based co-processed excipient |
US8628812B2 (en) | 2008-12-30 | 2014-01-14 | Pepsico, Inc. | Preservative system for acidic beverages based on sequestrants |
TR200900878A2 (tr) * | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar |
TWI480286B (zh) * | 2009-02-25 | 2015-04-11 | Merrion Res Iii Ltd | 雙膦酸鹽類組合物及藥物遞送 |
US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
SI2459176T1 (en) | 2009-07-31 | 2018-01-31 | Gruenenthal Gmbh | Crystallization process and bioavailability |
EP2458996B1 (en) | 2009-07-31 | 2016-09-07 | Thar Pharmaceuticals, Inc. | Novel oral forms of a phosphonic acid derivative |
EP2493905B1 (en) * | 2009-10-26 | 2016-11-30 | Warner Chilcott Company, LLC | Bisphosphonate compounds for treating bone metabolism disorders |
FR2954320B1 (fr) | 2009-12-17 | 2012-06-15 | Cll Pharma | Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels |
US9089484B2 (en) | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
FR2967576B1 (fr) * | 2010-11-18 | 2013-07-12 | Advicenne Pharma | Composition pharmaceutique comprenant du sel precurseur du cycle de krebs, en particulier du sel de citrate, et son utilisation comme medicament |
US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
KR20120105738A (ko) * | 2011-03-16 | 2012-09-26 | 현대약품 주식회사 | 장용코팅된 경구용 제제 |
KR20140047617A (ko) * | 2011-06-23 | 2014-04-22 | 바이엘 뉴질랜드 리미티드 | 마크로사이클릭 락톤 및 레바미솔을 포함하는 항-기생충 조성물 및 기생충 감염의 치료 방법 |
CN102885759A (zh) * | 2011-07-20 | 2013-01-23 | 杭州赛利药物研究所有限公司 | 利塞膦酸钠延释制剂及其制备方法 |
KR101324425B1 (ko) * | 2011-07-22 | 2013-11-01 | 동아에스티 주식회사 | 증가된 비스포스포네이트의 생체이용률을 가지는 경구투여 약제 |
US10588857B2 (en) | 2012-03-29 | 2020-03-17 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
US9694023B2 (en) | 2012-05-14 | 2017-07-04 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
US9861648B2 (en) | 2012-05-14 | 2018-01-09 | Antecip Boiventures Ii Llc | Osteoclast inhibitors for knee conditions |
US9925203B2 (en) | 2012-05-14 | 2018-03-27 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US9782421B1 (en) | 2012-05-14 | 2017-10-10 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
US10034890B2 (en) | 2012-05-14 | 2018-07-31 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10173986B2 (en) | 2012-05-14 | 2019-01-08 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
US9956238B2 (en) | 2014-05-15 | 2018-05-01 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US9795622B2 (en) | 2012-05-14 | 2017-10-24 | Antecip Bioventures Ii Llc | Neridronic acid for treating pain associated with a joint |
US9999629B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9901589B2 (en) | 2012-05-14 | 2018-02-27 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9895383B2 (en) | 2012-05-14 | 2018-02-20 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9956237B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US9827192B2 (en) | 2012-05-14 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10080765B2 (en) | 2012-05-14 | 2018-09-25 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9789128B2 (en) | 2012-05-14 | 2017-10-17 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10016446B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone |
US10350227B2 (en) | 2012-05-14 | 2019-07-16 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9844559B2 (en) | 2012-05-14 | 2017-12-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesions |
US9707245B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9999628B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9867840B2 (en) | 2014-05-27 | 2018-01-16 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9943531B2 (en) | 2014-08-08 | 2018-04-17 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US10004756B2 (en) | 2014-05-15 | 2018-06-26 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9956234B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
US9211257B2 (en) | 2012-05-14 | 2015-12-15 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US11654152B2 (en) | 2012-05-14 | 2023-05-23 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US9867839B2 (en) | 2012-05-14 | 2018-01-16 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
US10493085B2 (en) | 2012-05-14 | 2019-12-03 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
US9877977B2 (en) | 2012-05-14 | 2018-01-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10413561B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
US9827256B2 (en) | 2014-05-27 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating lower back pain |
US9820999B2 (en) | 2012-05-14 | 2017-11-21 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9770457B2 (en) | 2012-05-14 | 2017-09-26 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesion |
US9717747B2 (en) | 2012-05-14 | 2017-08-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US10092581B2 (en) | 2014-05-15 | 2018-10-09 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US10039773B2 (en) | 2012-05-14 | 2018-08-07 | Antecip Bioventures Ii Llc | Neridronic acid for treating arthritis |
US10016445B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10028908B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9707247B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US10111837B2 (en) | 2012-05-14 | 2018-10-30 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds |
US10413560B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
US10463682B2 (en) | 2012-05-14 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
US9949993B2 (en) | 2012-05-14 | 2018-04-24 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US9700570B2 (en) | 2014-05-27 | 2017-07-11 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10028969B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
MX350569B (es) * | 2012-12-03 | 2017-09-11 | Landsteiner Scient S A De C V | Composicion farmaceutica estable para el tratamiento de osteoporosis. |
BR112015023124A2 (pt) | 2013-03-14 | 2017-07-18 | Therabiome Llc | liberação de organismos probióticos e/ou agentes terapêuticos almejada para o trato gastrintestinal |
JP7211704B2 (ja) | 2015-01-29 | 2023-01-24 | ノヴォ ノルディスク アー/エス | Glp-1アゴニスト及び腸溶コーティングを含む錠剤 |
CN105267145B (zh) * | 2015-11-01 | 2019-06-21 | 袁旭东 | 双膦酸盐的自乳化配方和相关剂型 |
WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
BR112020019128A2 (pt) * | 2018-03-23 | 2021-01-12 | Palatin Technologies, Inc. | Formulação farmacêutica de liberação em trato gastrointestinal inferior; formulação farmacêutica de liberação no trato gastrointestinal inferior preparada por um processo; processo; formulação de liberação modificada; composição farmacêutica adequada para administração oral para tratamento de uma doença inflamatória intestinal; e método de tratamento de doença inflamatória intestinal (ibd) em um paciente humano com ibd |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859A (en) * | 1848-10-17 | Improvement in cultivators | ||
FR2548530B1 (fr) | 1983-07-07 | 1986-10-24 | Hatte Louis | Perfectionnement aux chaises paillees |
US5167947A (en) | 1989-10-26 | 1992-12-01 | Southwest Research Institute | Enhancement of absorption of radioprotective drugs |
US5356887A (en) | 1990-01-31 | 1994-10-18 | Merck & Co., Inc. | Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids |
CA2035179C (en) | 1990-01-31 | 2001-08-14 | Gerald S. Brenner | Pharmaceutical compositions containing insoluble salts of bisphosphonic acids |
ZA918168B (en) * | 1990-10-16 | 1993-04-14 | Takeda Chemical Industries Ltd | Prolonged release preparation and polymers thereof. |
FI89364C (fi) | 1990-12-20 | 1993-09-27 | Leiras Oy | Foerfarande foer framstaellning av nya, farmakologiskt anvaendbara metylenbisfosfonsyraderivat |
CA2122479C (en) | 1991-11-22 | 1998-08-25 | Richard John Dansereau | Risedronate delayed-release compositions |
EP0550385A1 (de) * | 1991-12-19 | 1993-07-07 | Ciba-Geigy Ag | Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten |
SE501389C2 (sv) | 1992-04-24 | 1995-01-30 | Leiras Oy | Farmaceutiskt preparat och förfarande för dess framställning |
US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
CN1072964C (zh) * | 1994-04-22 | 2001-10-17 | 山之内制药株式会社 | 结肠特异性释药系统 |
US5462932A (en) * | 1994-05-17 | 1995-10-31 | Merck & Co., Inc. | Oral liquid alendronate formulations |
JPH089120A (ja) | 1994-06-21 | 1996-01-12 | Nec Corp | 画データ転送制御方法 |
JP3672342B2 (ja) | 1994-09-26 | 2005-07-20 | アステラス製薬株式会社 | ビスホスホン酸又はその誘導体を含有する注射液とその安定化方法、及び注射液アンプル |
US5686106A (en) * | 1995-05-17 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
DE19615812A1 (de) * | 1996-04-20 | 1997-10-23 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation |
US5853759A (en) | 1996-05-17 | 1998-12-29 | Merck & Co.. Inc. | Effervescent alendronate formulation |
EP0939624B1 (en) | 1996-05-17 | 2003-12-17 | Merck & Co., Inc. | Effervescent bisphosphonate formulation |
US5735810A (en) | 1996-06-14 | 1998-04-07 | Becton Dickinson And Company | Device for the iontophoretic administration of bisphosphonates |
PL332496A1 (en) | 1996-10-04 | 1999-09-13 | Merck & Co Inc | Liquid alendronate preparations |
US6410782B1 (en) | 1997-07-09 | 2002-06-25 | Geange Ltd. | Diphosphonic acid salts for the treatment of osteoporosis |
US6432932B1 (en) * | 1997-07-22 | 2002-08-13 | Merck & Co., Inc. | Method for inhibiting bone resorption |
US5994329A (en) | 1997-07-22 | 1999-11-30 | Merck & Co., Inc. | Method for inhibiting bone resorption |
AU1525700A (en) | 1998-11-19 | 2000-06-05 | Board Of Trustees Of The University Of Arkansas, The | Increasing bone strength with selected bisphosphonates |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
SE9901272D0 (sv) | 1999-04-09 | 1999-04-09 | Astra Ab | New improved formulation |
DE60005502T2 (de) * | 1999-05-12 | 2004-06-24 | Yamasa Corp., Choshi | 4'-c-ethynyl-purin-nukleoside |
US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
AU761343B2 (en) | 1999-06-30 | 2003-06-05 | Moo-Won Byun | Apparatus for producing multiple channel duct assembly and method thereof |
AR024462A1 (es) * | 1999-07-01 | 2002-10-02 | Merck & Co Inc | Tabletas farmaceuticas |
AR021347A1 (es) * | 1999-10-20 | 2002-07-17 | Cipla Ltd | Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma |
AU2127200A (en) | 1999-11-02 | 2001-05-14 | Cipla Limited | A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereofand a process of preparing thereof |
US6677320B2 (en) * | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
CN1446093A (zh) | 2000-04-07 | 2003-10-01 | 得克萨斯系统大学董事会 | 两性离子型磷脂和双膦酸酯的独特组合物及其作为降低肠胃毒性的双膦酸酯释放系统的应用 |
US6468559B1 (en) | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
US6476006B2 (en) * | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
CN1492763B (zh) * | 2001-03-01 | 2012-05-23 | 艾米斯菲尔技术有限公司 | 用于递送二膦酸盐的组合物 |
ITMI20011337A1 (it) | 2001-06-26 | 2002-12-26 | Farmatron Ltd | Composizioni farmaceutiche orali a rilascio modificato del principio attivo |
CA2454200A1 (en) | 2001-07-17 | 2003-01-30 | Teva Pharmaceutical Industries Ltd. | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
WO2003051373A1 (en) | 2001-12-13 | 2003-06-26 | Merck & Co., Inc. | Liquid bisphosphonate formulations for bone disorders |
US20050070504A1 (en) * | 2001-12-21 | 2005-03-31 | The Procter & Gamble Co. | Risedronate compositions and their methods of use |
BR0106601A (pt) | 2001-12-21 | 2003-09-09 | Libbs Farmaceutica Ltda | Composição farmacêutica contendo bisfosfonato para o tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato, seu uso na preparação de medicamento para o tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato, método de tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato |
JP3869456B2 (ja) | 2003-01-17 | 2007-01-17 | テバ ファーマシューティカル インダストリーズ リミティド | 鉄含有量が非常に低いリセドロン酸ナトリウム |
CA2528519A1 (en) | 2003-06-11 | 2005-02-24 | Novacea, Inc. | Treatment of lung cancer with active vitamin d compounds in combination with other treatments |
US20050182028A1 (en) * | 2004-02-13 | 2005-08-18 | Chen Chih-Ming J. | Pharmaceutical formulation for oral delivery of bisphosphates |
US7785619B2 (en) * | 2004-04-08 | 2010-08-31 | Micro Nutrient, Llc | Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens |
CA2566798A1 (en) * | 2004-05-24 | 2005-12-08 | The Procter & Gamble Company | Enteric solid oral dosage form of bisphosphonate containing a chelating agent |
US20080287400A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
US20080286359A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US7645460B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
US20060069069A1 (en) * | 2004-07-15 | 2006-03-30 | Nanobac Pharmaceuticals, Inc. | Methods and compositions for the administration of calcium chelators, bisphosponates and/or citrate compounds and their pharmaceutical uses |
WO2006020009A1 (en) | 2004-07-23 | 2006-02-23 | The Procter & Gamble Company | Solid oral dosage form of a bisphosphonate containing a chelating agent |
US20060134190A1 (en) * | 2004-12-16 | 2006-06-22 | Banner Pharmacaps Inc. | Formulations of bisphosphonate drugs with improved bioavailability |
TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
EP1865928A1 (en) * | 2005-03-17 | 2007-12-19 | Elan Pharma International Limited | Nanoparticulate biphosphonate compositions |
US20070003512A1 (en) * | 2005-06-20 | 2007-01-04 | Stockel Richard F | Bisphosphonate resinates |
EP2007397B1 (en) * | 2006-04-07 | 2013-07-24 | Merrion Research III Limited | Solid oral dosage form containing an enhancer |
-
2005
- 2005-04-15 US US11/106,816 patent/US7645459B2/en active Active
- 2005-11-23 RU RU2007136046/15A patent/RU2381791C2/ru active
- 2005-11-23 CN CN201410192870.3A patent/CN104027323A/zh active Pending
- 2005-11-23 CA CA002602188A patent/CA2602188C/en active Active
- 2005-11-23 EP EP05852255A patent/EP1868584A1/en not_active Ceased
- 2005-11-23 KR KR1020077023276A patent/KR101070205B1/ko active IP Right Grant
- 2005-11-23 KR KR1020107028875A patent/KR101280138B1/ko active IP Right Grant
- 2005-11-23 MX MX2007012821A patent/MX2007012821A/es active IP Right Grant
- 2005-11-23 AU AU2005330654A patent/AU2005330654B2/en not_active Withdrawn - After Issue
- 2005-11-23 CN CNA2005800494833A patent/CN101166519A/zh active Pending
- 2005-11-23 IN IN827DEN2012 patent/IN2012DN00827A/en unknown
- 2005-11-23 WO PCT/US2005/042887 patent/WO2006112889A1/en active Application Filing
- 2005-11-23 SM SM200700047T patent/SMAP200700047A/it unknown
- 2005-11-23 BR BRPI0520082-2A patent/BRPI0520082A2/pt not_active Application Discontinuation
- 2005-11-23 JP JP2008506439A patent/JP4788765B2/ja not_active Expired - Fee Related
- 2005-11-23 CA CA002675652A patent/CA2675652A1/en not_active Abandoned
-
2007
- 2007-10-07 IL IL186339A patent/IL186339A0/en unknown
- 2007-10-29 MA MA30333A patent/MA29681B1/fr unknown
- 2007-11-14 NO NO20075834A patent/NO20075834L/no not_active Application Discontinuation
-
2009
- 2009-12-14 US US12/637,100 patent/US8246989B2/en active Active
-
2012
- 2012-07-09 US US13/544,377 patent/US8535718B2/en active Active
-
2013
- 2013-08-12 US US13/964,359 patent/US20130331361A1/en not_active Abandoned
-
2019
- 2019-08-04 IL IL268462A patent/IL268462A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2005330654B2 (en) | 2011-06-23 |
RU2381791C2 (ru) | 2010-02-20 |
JP2008535912A (ja) | 2008-09-04 |
CA2602188A1 (en) | 2006-10-26 |
AU2005330654A1 (en) | 2006-10-26 |
CN101166519A (zh) | 2008-04-23 |
US20130012478A1 (en) | 2013-01-10 |
EP1868584A1 (en) | 2007-12-26 |
SMP200700047B (it) | 2007-11-21 |
IN2012DN00827A (no) | 2015-06-26 |
BRPI0520082A2 (pt) | 2009-04-14 |
US20130331361A1 (en) | 2013-12-12 |
MA29681B1 (fr) | 2008-08-01 |
KR101280138B1 (ko) | 2013-06-28 |
KR20070111551A (ko) | 2007-11-21 |
JP4788765B2 (ja) | 2011-10-05 |
SMAP200700047A (it) | 2007-11-21 |
IL186339A0 (en) | 2008-01-20 |
RU2007136046A (ru) | 2009-05-20 |
CN104027323A (zh) | 2014-09-10 |
MX2007012821A (es) | 2007-11-20 |
IL268462A (en) | 2019-09-26 |
US20100086593A1 (en) | 2010-04-08 |
CA2602188C (en) | 2009-10-13 |
US8246989B2 (en) | 2012-08-21 |
CA2675652A1 (en) | 2006-10-26 |
KR101070205B1 (ko) | 2011-10-06 |
US8535718B2 (en) | 2013-09-17 |
US7645459B2 (en) | 2010-01-12 |
US20050260262A1 (en) | 2005-11-24 |
KR20110002887A (ko) | 2011-01-10 |
WO2006112889A1 (en) | 2006-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20075834L (no) | Doseringsformer for risendronat | |
NO20065969L (no) | Doseringsformer for bifosfonater | |
MX2009002196A (es) | Oblea de buprenorfina para terapia de sustitucion de farmacos. | |
CY1119498T1 (el) | Συντηγμενα πολυπεπτιδια λεπτινης-abd με ενισχυμενη διαρκεια δρασης | |
EA200701519A1 (ru) | Живая аттенуированная ротавирусная вакцина для перорального введения | |
ATE529113T1 (de) | Salze von kalium-atp-kanal-öffnern und ihre verwendungen | |
NO20092323L (no) | Doserings- og drivmekanisme for legemiddelleveringsanordning | |
NO20070597L (no) | Medikamtenter for a behandle kronisk respiratorisk sykdom. | |
NO20072931L (no) | Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva | |
IL196425A (en) | Dosage unit for oral administration containing ibuprofen and pamotidine | |
NO20081863L (no) | Forhindring og behandling av gastrointestinal og blaerelidelse assosiert med kemoterapi eller stralingsterapi ved bruk av aktiv vitamin D forbindelse | |
BR112012000862A8 (pt) | composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamento | |
BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
DK1836665T3 (da) | Fremgangsmåde til specialtilpasset afgivelse af medikamentkombinationsprodukter med variabel dosis til individualisering af terapier | |
NO20080244L (no) | Doseringsstyring for prasugrel | |
WO2007081486A3 (en) | Oral administration of defensins to treat intestinal diseases | |
ATE361065T1 (de) | Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes | |
TNSN08385A1 (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
TR200200913T2 (tr) | Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları. | |
RU2007129408A (ru) | Способ выращивания поросят в период откорма | |
Nakajima | Crawling sensation in an elderly patient: case report | |
Baek | Nephrotic syndrome: case report | |
Data | Product Update | |
Teivelis | Constipation, Gastrooesophageal reflux, somnolence and dry mouth: 5 case reports | |
FR2939023B1 (fr) | Dispositif d'administration d'un produit de traitement therapeutique, sanitaire ou autre |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |